PRLD
Prelude Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$274.72M
P/E Ratio
—
EPS
$-1.29
Beta
0.71
52W High
$4.82
52W Low
$0.72
50-Day MA
$2.99
200-Day MA
$1.83
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware.
Fundamentals
| Revenue (TTM) | $12.14M |
| Gross Profit (TTM) | $12.14M |
| EBITDA | $-101.56M |
| Operating Margin | -284.50% |
| Return on Equity | -99.50% |
| Return on Assets | -40.70% |
| Revenue/Share (TTM) | $0.16 |
| Book Value | $0.83 |
| Price-to-Book | 3.75 |
| Price-to-Sales (TTM) | 22.63 |
| EV/Revenue | 14.12 |
| EV/EBITDA | -0.54 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 41.00% |
| Shares Outstanding | $43.77M |
| Float | $14.56M |
| % Insiders | 10.50% |
| % Institutions | 59.17% |
Historical Volatility
HV 10-Day
116.52%
HV 20-Day
103.47%
HV 30-Day
110.06%
HV 60-Day
124.99%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($5.17 target)
1
Strong Buy2
BuyData last updated: 4/14/2026